首页> 外文期刊>ACS applied materials & interfaces >Endogenous Polysialic Acid Based Micelles for Calmodulin Antagonist Delivery against Vascular Dementia
【24h】

Endogenous Polysialic Acid Based Micelles for Calmodulin Antagonist Delivery against Vascular Dementia

机译:内源性聚唾液酸基胶束用于钙调蛋白拮抗剂递送抗血管性痴呆

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical treatment for vascular dementia still remains a challenge mainly due to the blood brain barrier (BBB). Here, a micelle based on polysialic acid (PSA), which is a hydrophilic and endogenous carbohydrate polymer, was designed to deliver calmodulin antagonist for therapy of vascular dementia. PSA was first chemically conjugated with octadecylamine (ODA), and the obtained PSA ODA copolymer could self-assemble into micelle in aqueous solution with a 120.0 mu g/mL critical micelle concentration. The calmodulin antagonist loaded PSA ODA micelle, featuring sustained drug release behavior over a period of 72 h with a 3.6% (w/w) drug content and a 107.0 +/- 4.0 nm size was then fabricated. The PSA ODA micelle could cross the BBB mainly via active endocytosis by brain endothelial cells followed by transcytosis. In a water maze test for spatial learning, calmodulin antagonist loaded PSA ODA micelle significantly reduced the escape latencies of right unilateral common carotid arteries occlusion (rUCCAO) mice with dosage significantly reduced versus free drug. The decrease of hippocampal phospho-CaMKII (Thr286/287) and phospho-synapsin I (Ser603) was partially restored in rUCCAO mice following calmodulin antagonist loaded PSA ODA micelle treatment. Consistent with the restored CalVall phosphorylation, the elevation of BrdU/NeuN double-positive cells in the same context was also observed. Overall, the PSA ODA micelle developed from the endogenous material might promote the development of therapeutic approaches for improving the efficacy of brain-targeted drug delivery and have great potential for vascular dementia treatment.
机译:血管性痴呆的临床治疗仍然是一个挑战,主要是由于血脑屏障(BBB)。在这里,基于聚唾液酸(PSA)的胶束是一种亲水性和内源性的碳水化合物聚合物,被设计用来递送钙调蛋白拮抗剂来治疗血管性痴呆。首先将PSA与十八烷基胺(ODA)化学偶联,所得PSA ODA共聚物可以在水溶液中自组装成临界胶束浓度为120.0μg / mL的胶束。然后制备了钙调蛋白拮抗剂负载的PSA ODA胶束,其特征是在72小时内持续释放药物,药物含量为3.6%(w / w),尺寸为107.0 +/- 4.0 nm。 PSA ODA胶束可能主要通过脑内皮细胞的主动内吞作用和随后的胞吞作用而穿过血脑屏障。在用于空间学习的水迷宫测试中,装载钙调蛋白拮抗剂的PSA ODA胶束显着降低了右单侧颈总动脉闭塞(rUCCAO)小鼠的逃逸潜伏期,剂量与游离药物相比明显降低。钙调蛋白拮抗剂负载的PSA ODA胶束处理后,rUCCAO小鼠的海马磷酸CaMKII(Thr286 / 287)和磷酸突触素I(Ser603)的减少部分恢复。与恢复的CalVall磷酸化一致,在相同情况下还观察到BrdU / NeuN双阳性细胞的升高。总体而言,由内源性材料开发的PSA ODA胶束可能会促进治疗方法的发展,以改善脑靶向药物的输送效率,并具有治疗血管性痴呆的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号